Release Date: June 26, 2008

Program Overview

Type 2 diabetes (T2D) is a complex and heterogeneous disorder associated with numerous pathophysiologic defects. Many conventional therapies address only a single defect, not the constellation of pathophysiologic challenges associated with T2D. Further, most conventional therapies do not offer the potential to correct underlying pathophysiologic defects and, as such, tend to lose efficacy as the disease progresses. Conventional therapies are associated with a number of perceived clinical challenges, including weight gain and hypoglycemia. Incretinbased therapies, however, address numerous pathophysiologic defects in T2D with limited side effects. They offer the potential to alter the course of the disease.

Breaking News on Incretin-Based Therapies: Summary Conference Report in Conjunction With the 2008 American Diabetes Association's 68th Annual Scientific Sessions is an educational activity designed to increase awareness and understanding of the role of incretin-based therapies in the treatment of patients with T2D. The report provides a practical overview of the most clinically relevant data on incretin-based therapies presented through posters and oral presentations at the 68th Scientific Sessions of the American Diabetes Association in San Francisco, June 6-10, 2008.

Intended Audience

This activity is intended for endocrinologists, diabetologists, diabetes educators, nurses, and other healthcare professionals (HCPs) who treat patients with T2D.

Learning Objectives

After participating in this activity, participants should be able to:

• Summarize current data that describe the clinical efficacy and safety of DPP-4 inhibitors for the treatment of T2D
• Discuss current data that describe the clinical efficacy and safety of incretin mimetics for the treatment of T2D
• Discuss the appropriate clinical application of incretin-based therapies, including proper patient selection based on clinical need and current glycemic control

Expiration Date: June 26, 2009

CME/CNE Accreditation Statements For Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Institute for Medical and Nursing Education (IMNE) and International Medical Press (IMP). IMNE is accredited by the ACCME to provide continuing medical education for physicians.

IMNE designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For Nurses

IMNE is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's (ANCC's) Committee on Accreditation.

IMNE designates this educational activity for 0.75 contact hours (0.075 CEUs). Accreditation by the ANCC's Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.

Acknowledgment of Commercial Support

This activity was supported by an educational grant from Novo Nordisk Inc.

Disclosures

Conflict of interest disclosures can be found on pages 3-4 of the summary conference report.